...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Dengue dynamics and vaccine cost-effectiveness in Brazil.
【24h】

Dengue dynamics and vaccine cost-effectiveness in Brazil.

机译：巴西的登革热动态和疫苗成本效益。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Recent Phase 2b dengue vaccine trials have demonstrated the safety of the vaccine and estimated the vaccine efficacy with further trials underway. In anticipation of vaccine roll-out, cost-effectiveness analysis of potential vaccination policies that quantify the dynamics of disease transmission are fundamental to the optimal allocation of available doses. We developed a dengue transmission and vaccination model and calculated, for a range of vaccination costs and willingness-to-pay thresholds, the level of vaccination coverage necessary to sustain herd-immunity, the price at which vaccination is cost-effective and is cost-saving, and the sensitivity of our results to parameter uncertainty. We compared two vaccine efficacy scenarios, one a more optimistic scenario and another based on the recent lower-than-expected efficacy from the latest clinical trials. We found that herd-immunity may be achieved by vaccinating 82% (95% CI 58-100%) of the population at a vaccine efficacy of 70%. At this efficacy, vaccination may be cost-effective for vaccination costs up to US$ 534 (95% CI $369-1008) per vaccinated individual and cost-saving up to $204 (95% CI $39-678). At the latest clinical trial estimates of an average of 30% vaccine efficacy, vaccination may be cost-effective and cost-saving at costs of up to $237 (95% CI $159-512) and $93 (95% CI $15-368), respectively. Our model provides an assessment of the cost-effectiveness of dengue vaccination in Brazil and incorporates the effect of herd immunity into dengue vaccination cost-effectiveness. Our results demonstrate that at the relatively low vaccine efficacy from the recent Phase 2b dengue vaccine trials, age-targeted vaccination may still be cost-effective provided the total vaccination cost is sufficiently low.Digital Object Identifier http://dx.doi.org/10.1016/j.vaccine.2013.06.036
机译：最近的2b期登革热疫苗试验已经证明了该疫苗的安全性，并通过进一步的试验评估了疫苗的功效。在预期推出疫苗的过程中，对可能的疫苗接种策略进行成本效益分析以量化疾病传播的动态，这是最佳分配可用剂量的基础。我们开发了登革热传播和疫苗接种模型，并针对一系列疫苗接种成本和支付意愿门槛值，计算了维持牛群免疫所必需的疫苗接种水平，以及疫苗具有成本效益和成本效益的价格，保存，以及我们的结果对参数不确定性的敏感性。我们比较了两种疫苗功效方案，一种是较为乐观的方案，另一种是根据最新临床试验中近期低于预期的功效。我们发现，以70％的疫苗效力接种82％（95％CI 58-100％）的人群可以实现畜群免疫。在这种功效下，疫苗接种可能具有成本效益，因为每个疫苗接种者的疫苗接种成本最高可达534美元（95％CI $ 369-1008），节省成本最高可达$ 204（95％CI $ 39-678）。根据最新的平均30％疫苗功效的临床试验估计，疫苗接种可能合算且节省成本，费用分别高达237美元（95％CI为159-512美元）和93美元（95％CI为15-368美元），分别。我们的模型提供了对巴西登革热疫苗接种成本效益的评估，并将牛群免疫的影响纳入了登革热疫苗接种成本效益。我们的结果表明，在最近的2b期登革热疫苗试验中相对较低的疫苗效力下，如果总疫苗接种成本足够低，则针对年龄的疫苗接种仍可能具有成本效益。Digital Object Identifier http://dx.doi.org /10.1016/j.vaccine.2013.06.036

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号